File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Allogeneic graft-versus-hepatoblastoma effect

TitleAllogeneic graft-versus-hepatoblastoma effect
Authors
KeywordsHematopoietic stem cell transplantation
Graft-versus-tumor effect
Hepatoblastoma
Issue Date2006
Citation
Pediatric Blood and Cancer, 2006, v. 46, n. 4, p. 501-505 How to Cite?
AbstractAlthough the survival rate for pediatric patients with hepatoblastoma has improved, prognosis is still poor when the disease is unresectable and refractory to chemotherapy. Therefore, novel approaches are warranted. Herein, we describe a patient with recurrent metastatic hepatoblastoma who received a nonmyeloablative hematopoietic stem cell transplantation from an HLA-matched unrelated donor. After withdrawal of immunosuppressant and establishment of full donor T-cell engraftment, the tumor regressed and serum α-fetoprotein level decreased in concurrence with the onset of graft-versus-host disease (GVHD). Her disease recurred when GVHD resolved. This patient's clinical course provides evidence for the probable existence of allogeneic graft-versus- hepatoblastoma effect. © 2005 Wiley-Liss, Inc.
Persistent Identifierhttp://hdl.handle.net/10722/294413
ISSN
2020 Impact Factor: 3.167
2020 SCImago Journal Rankings: 1.116
ISI Accession Number ID

 

DC FieldValueLanguage
dc.contributor.authorInaba, Hiroto-
dc.contributor.authorHandgretinger, Rupert-
dc.contributor.authorFurman, Wayne-
dc.contributor.authorHale, Gregory-
dc.contributor.authorLeung, Wing-
dc.date.accessioned2020-12-03T08:22:40Z-
dc.date.available2020-12-03T08:22:40Z-
dc.date.issued2006-
dc.identifier.citationPediatric Blood and Cancer, 2006, v. 46, n. 4, p. 501-505-
dc.identifier.issn1545-5009-
dc.identifier.urihttp://hdl.handle.net/10722/294413-
dc.description.abstractAlthough the survival rate for pediatric patients with hepatoblastoma has improved, prognosis is still poor when the disease is unresectable and refractory to chemotherapy. Therefore, novel approaches are warranted. Herein, we describe a patient with recurrent metastatic hepatoblastoma who received a nonmyeloablative hematopoietic stem cell transplantation from an HLA-matched unrelated donor. After withdrawal of immunosuppressant and establishment of full donor T-cell engraftment, the tumor regressed and serum α-fetoprotein level decreased in concurrence with the onset of graft-versus-host disease (GVHD). Her disease recurred when GVHD resolved. This patient's clinical course provides evidence for the probable existence of allogeneic graft-versus- hepatoblastoma effect. © 2005 Wiley-Liss, Inc.-
dc.languageeng-
dc.relation.ispartofPediatric Blood and Cancer-
dc.subjectHematopoietic stem cell transplantation-
dc.subjectGraft-versus-tumor effect-
dc.subjectHepatoblastoma-
dc.titleAllogeneic graft-versus-hepatoblastoma effect-
dc.typeArticle-
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1002/pbc.20404-
dc.identifier.pmid15806543-
dc.identifier.scopuseid_2-s2.0-33644670040-
dc.identifier.volume46-
dc.identifier.issue4-
dc.identifier.spage501-
dc.identifier.epage505-
dc.identifier.eissn1545-5017-
dc.identifier.isiWOS:000235814700017-
dc.identifier.issnl1545-5009-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats